A process evaluation of Ontario, Canada’s 2023–24 older-adult RSV vaccination program
Respiratory syncytial virus (RSV) is a major cause of respiratory illness in older adults. During the 2023–2024 respiratory season, Ontario was the first and only province in Canada to launch a publicly funded RSV vaccination program for older adults. A process evaluation of the program was complete...
Saved in:
| Main Authors: | Reed Morrison, Janice Sarmiento, Jamie Park, Gillian Lim, Christina Renda, Michael Whelan, Allison McGeer, Tara Harris, Sarah E. Wilson |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2025.2550089 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Hospitalizations for respiratory syncytial virus (RSV) in Sicily from 2008 to 2021: clinical features and predictors of severity
by: Anna Condemi, et al.
Published: (2025-07-01) -
Seroprevalence of RSV antibodies in a contemporary (2022-2023) cohort of adults
by: Lara I. Teodoro, et al.
Published: (2025-09-01) -
Combining Intramuscular and Intranasal Immunization With the MF59‐Adjuvanted Respiratory Syncytial Virus Pre‐Fusion Protein Subunit Vaccine Induces Potent Humoral and Cellular Immune Responses in Mice
by: Jie Shi, et al.
Published: (2025-08-01) -
Healthcare Resource Utilization and Economic Outcomes of RSV-Hospitalized Patients Aged ≥ 60 Years: A Retrospective Cohort Study
by: Anna Puggina, et al.
Published: (2025-02-01) -
Pediatric respiratory syncytial virus rehospitalization rate – a retrospective observational study from Switzerland
by: Naomi Rupp, et al.
Published: (2025-07-01)